Lipid desaturation – the next step in targeting lipogenesis in cancer?

FEBS Journal

Volumn , Issue , 2016, Pages 2767-2778

  Peck, Barrie ^a   Schulze, Almut ^b,c  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c Comprehensive Cancer Center Mainfranken ^*  (Germany)

Author keywords

cancer; hypoxia; lipid desaturation; lipid synthesis; metabolism; microenvironment; SCD

Indexed keywords

ACETYL COENZYME A CARBOXYLASE INHIBITOR; ACYL COENZYME A DESATURASE; FATTY ACID; FATTY ACID SYNTHASE; K RAS PROTEIN; RAPAMYCIN; SORAPHEN A; STEROL REGULATORY ELEMENT BINDING PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER THERAPY; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; DRUG MECHANISM; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVITY; FATTY ACID DESATURATION; FATTY ACID SYNTHESIS; HUMAN; HYPOXIA; LIPID METABOLISM; LIPID PEROXIDATION; LIPOGENESIS; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING;

EID: 84982949213     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.13681     Document Type: Article

References (81)

1. Weiss L, Hoffmann GE, Schreiber R, Andres H, Fuchs E, Korber E & Kolb HJ (1986) Fatty-acid biosynthesis in man, a pathway of minor importance. Purification, optimal assay conditions, and organ distribution of fatty-acid synthase. Biol Chem Hoppe-Seyler 367, 905–912.
2. Medes G, Thomas A & Weinhouse S (1953) Metabolism of neoplastic tissue. IV. A study of lipid synthesis in neoplastic tissue slices in vitro. Cancer Res 13, 27–29.
3. Kuhajda FP, Jenner K, Wood FD, Hennigar RA, Jacobs LB, Dick JD & Pasternack GR (1994) Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc Natl Acad Sci USA 91, 6379–6383.
4. Bandyopadhyay S, Pai SK, Watabe M, Gross SC, Hirota S, Hosobe S, Tsukada T, Miura K, Saito K, Markwell SJ et al. (2005) FAS expression inversely correlates with PTEN level in prostate cancer and a PI 3-kinase inhibitor synergizes with FAS siRNA to induce apoptosis. Oncogene 24, 5389–5395.
5. Wang HQ, Altomare DA, Skele KL, Poulikakos PI, Kuhajda FP, Di Cristofano A & Testa JR (2005) Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells. Oncogene 24, 3574–3582.
6. Zaytseva YY, Rychahou PG, Gulhati P, Elliott VA, Mustain WC, O'Connor K, Morris AJ, Sunkara M, Weiss HL, Lee EY et al. (2012) Inhibition of fatty acid synthase attenuates CD44-associated signaling and reduces metastasis in colorectal cancer. Cancer Res 72, 1504–1517.
7. Menendez JA & Lupu R (2007) Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev 7, 763–777.
8. Santos CR & Schulze A (2012) Lipid metabolism in cancer. FEBS J 279, 2610–2623.
9. Currie E, Schulze A, Zechner R, Walther TC & Farese RV Jr (2013) Cellular fatty acid metabolism and cancer. Cell Metab 18, 153–161.
10. Menendez JA, Colomer R & Lupu R (2005) Why does tumor-associated fatty acid synthase (oncogenic antigen-519) ignore dietary fatty acids? Med Hypotheses 64, 342–349.
11. Hochachka PW, Rupert JL, Goldenberg L, Gleave M & Kozlowski P (2002) Going malignant: the hypoxia-cancer connection in the prostate. BioEssays 24, 749–757.
12. Kidani Y, Elsaesser H, Hock MB, Vergnes L, Williams KJ, Argus JP, Marbois BN, Komisopoulou E, Wilson EB, Osborne TF et al. (2013) Sterol regulatory element-binding proteins are essential for the metabolic programming of effector T cells and adaptive immunity. Nat Immunol 14, 489–499.
13. Berod L, Friedrich C, Nandan A, Freitag J, Hagemann S, Harmrolfs K, Sandouk A, Hesse C, Castro CN, Bahre H et al. (2014) De novo fatty acid synthesis controls the fate between regulatory T and T helper 17 cells. Nat Med 20, 1327–1333.
14. Yang K, Shrestha S, Zeng H, Karmaus PW, Neale G, Vogel P, Guertin DA, Lamb RF & Chi H (2013) T cell exit from quiescence and differentiation into Th2 cells depend on Raptor-mTORC1-mediated metabolic reprogramming. Immunity 39, 1043–1056.
15. Lochner M, Berod L & Sparwasser T (2015) Fatty acid metabolism in the regulation of T cell function. Trends Immunol 36, 81–91.
16. Denechaud PD, Lopez-Mejia IC, Giralt A, Lai Q, Blanchet E, Delacuisine B, Nicolay BN, Dyson NJ, Bonner C, Pattou F et al. (2016) E2F1 mediates sustained lipogenesis and contributes to hepatic steatosis. J Clin Investig 126, 137–150.
17. Nohturfft A & Zhang SC (2009) Coordination of lipid metabolism in membrane biogenesis. Annu Rev Cell Dev Biol 25, 539–566.
18. Horton JD (2002) Sterol regulatory element-binding proteins: transcriptional activators of lipid synthesis. Biochem Soc Trans 30, 1091–1095.
19. Bengoechea-Alonso MT & Ericsson J (2007) SREBP in signal transduction: cholesterol metabolism and beyond. Curr Opin Cell Biol 19, 215–222.
20. Brown MS & Goldstein JL (1997) The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89, 331–340.
21. Walker AK, Jacobs RL, Watts JL, Rottiers V, Jiang K, Finnegan DM, Shioda T, Hansen M, Yang F, Niebergall LJ et al. (2011) A conserved SREBP-1/phosphatidylcholine feedback circuit regulates lipogenesis in metazoans. Cell 147, 840–852.
22. Yang YA, Han WF, Morin PJ, Chrest FJ & Pizer ES (2002) Activation of fatty acid synthesis during neoplastic transformation: role of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Exp Cell Res 279, 80–90.
23. Porstmann T, Griffiths B, Chung YL, Delpuech O, Griffiths JR, Downward J & Schulze A (2005) PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP. Oncogene 24, 6465–6481.
24. Porstmann T, Santos CR, Griffiths B, Cully M, Wu M, Leevers S, Griffiths JR, Chung YL & Schulze A (2008) SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab 8, 224–236.
25. Duvel K, Yecies JL, Menon S, Raman P, Lipovsky AI, Souza AL, Triantafellow E, Ma Q, Gorski R, Cleaver S et al. (2010) Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell 39, 171–183.
26. Peterson TR, Sengupta SS, Harris TE, Carmack AE, Kang SA, Balderas E, Guertin DA, Madden KL, Carpenter AE, Finck BN et al. (2011) mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell 146, 408–420.
27. Han J, Li E, Chen L, Zhang Y, Wei F, Liu J, Deng H & Wang Y (2015) The CREB coactivator CRTC2 controls hepatic lipid metabolism by regulating SREBP1. Nature 524, 243–246.
28. Li S, Brown MS & Goldstein JL (2010) Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis. Proc Natl Acad Sci USA 107, 3441–3446.
29. Yuan M, Pino E, Wu L, Kacergis M & Soukas AA (2012) Identification of Akt-independent regulation of hepatic lipogenesis by mammalian target of rapamycin (mTOR) complex 2. J Biol Chem 287, 29579–29588.
30. Sundqvist A, Bengoechea-Alonso MT, Ye X, Lukiyanchuk V, Jin J, Harper JW & Ericsson J (2005) Control of lipid metabolism by phosphorylation-dependent degradation of the SREBP family of transcription factors by SCF(Fbw7). Cell Metab 1, 379–391.
31. Li Y, Xu S, Mihaylova MM, Zheng B, Hou X, Jiang B, Park O, Luo Z, Lefai E, Shyy JY et al. (2011) AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab 13, 376–388.
32. Hardie DG (2007) AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 8, 774–785.
33. Ricoult SJ, Yecies JL, Ben-Sahra I & Manning BD (2015) Oncogenic PI3K and K-Ras stimulate de novo lipid synthesis through mTORC1 and SREBP. Oncogene. doi: 10.1038/onc.2015.179.
34. Paton CM & Ntambi JM (2009) Biochemical and physiological function of stearoyl-CoA desaturase. Am J Physiol Endocrinol Metab 297, E28–E37.
35. Zhang L, Ge L, Parimoo S, Stenn K & Prouty SM (1999) Human stearoyl-CoA desaturase: alternative transcripts generated from a single gene by usage of tandem polyadenylation sites. Biochem J 340 (Pt 1), 255–264.
36. Igal RA (2010) Stearoyl-CoA desaturase-1: a novel key player in the mechanisms of cell proliferation, programmed cell death and transformation to cancer. Carcinogenesis 31, 1509–1515.
37. Fritz V, Benfodda Z, Rodier G, Henriquet C, Iborra F, Avances C, Allory Y, de la Taille A, Culine S, Blancou H et al. (2010) Abrogation of de novo lipogenesis by stearoyl-CoA desaturase 1 inhibition interferes with oncogenic signaling and blocks prostate cancer progression in mice. Mol Cancer Ther 9, 1740–1754.
38. Huang GM, Jiang QH, Cai C, Qu M & Shen W (2015) SCD1 negatively regulates autophagy-induced cell death in human hepatocellular carcinoma through inactivation of the AMPK signaling pathway. Cancer Lett 358, 180–190.
39. von Roemeling CA, Marlow LA, Wei JJ, Cooper SJ, Caulfield TR, Wu K, Tan WW, Tun HW & Copland JA (2013) Stearoyl-CoA desaturase 1 is a novel molecular therapeutic target for clear cell renal cell carcinoma. Clin Cancer Res 19, 2368–2380.
40. Holder AM, Gonzalez-Angulo AM, Chen H, Akcakanat A, Do KA, Fraser Symmans W, Pusztai L, Hortobagyi GN, Mills GB & Meric-Bernstam F (2013) High stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients. Breast Cancer Res Treat 137, 319–327.
41. Scaglia N & Igal RA (2008) Inhibition of Stearoyl-CoA Desaturase 1 expression in human lung adenocarcinoma cells impairs tumorigenesis. Int J Oncol 33, 839–850.
42. Hess D, Chisholm JW & Igal RA (2010) Inhibition of stearoylCoA desaturase activity blocks cell cycle progression and induces programmed cell death in lung cancer cells. PLoS One 5, e11394.
43. Kim SJ, Choi H, Park SS, Chang C & Kim E (2011) Stearoyl CoA desaturase (SCD) facilitates proliferation of prostate cancer cells through enhancement of androgen receptor transactivation. Mol Cells 31, 371–377.
44. Mason P, Liang B, Li L, Fremgen T, Murphy E, Quinn A, Madden SL, Biemann HP, Wang B, Cohen A et al. (2012) SCD1 inhibition causes cancer cell death by depleting mono-unsaturated fatty acids. PLoS One 7, e33823.
45. Scaglia N, Chisholm JW & Igal RA (2009) Inhibition of stearoylCoA desaturase-1 inactivates acetyl-CoA carboxylase and impairs proliferation in cancer cells: role of AMPK. PLoS One 4, e6812.
46. Roongta UV, Pabalan JG, Wang X, Ryseck RP, Fargnoli J, Henley BJ, Yang WP, Zhu J, Madireddi MT, Lawrence RM et al. (2011) Cancer cell dependence on unsaturated fatty acids implicates stearoyl-CoA desaturase as a target for cancer therapy. Mol Cancer Res 9, 1551–1561.
47. Hilvo M, Denkert C, Lehtinen L, Muller B, Brockmoller S, Seppanen-Laakso T, Budczies J, Bucher E, Yetukuri L, Castillo S et al. (2011) Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression. Cancer Res 71, 3236–3245.
48. Ide Y, Waki M, Hayasaka T, Nishio T, Morita Y, Tanaka H, Sasaki T, Koizumi K, Matsunuma R, Hosokawa Y et al. (2013) Human breast cancer tissues contain abundant phosphatidylcholine(36ratio1) with high stearoyl-CoA desaturase-1 expression. PLoS One 8, e61204.
49. Wang D & Dubois RN (2010) Eicosanoids and cancer. Nat Rev 10, 181–193.
50. Nashed M, Chisholm JW & Igal RA (2012) Stearoyl-CoA desaturase activity modulates the activation of epidermal growth factor receptor in human lung cancer cells. Exp Biol Med 237, 1007–1017.
51. Ntambi JM, Miyazaki M, Stoehr JP, Lan H, Kendziorski CM, Yandell BS, Song Y, Cohen P, Friedman JM & Attie AD (2002) Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity. Proc Natl Acad Sci USA 99, 11482–11486.
52. Flowers MT, Keller MP, Choi Y, Lan H, Kendziorski C, Ntambi JM & Attie AD (2008) Liver gene expression analysis reveals endoplasmic reticulum stress and metabolic dysfunction in SCD1-deficient mice fed a very low-fat diet. Physiol Genomics 33, 361–372.
53. Bernales S, Papa FR & Walter P (2006) Intracellular signaling by the unfolded protein response. Annu Rev Cell Dev Biol 22, 487–508.
54. Ron D & Walter P (2007) Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 8, 519–529.
55. Rutkowski DT, Arnold SM, Miller CN, Wu J, Li J, Gunnison KM, Mori K, Sadighi Akha AA, Raden D & Kaufman RJ (2006) Adaptation to ER stress is mediated by differential stabilities of pro-survival and pro-apoptotic mRNAs and proteins. PLoS Biol 4, e374.
56. Minville-Walz M, Pierre AS, Pichon L, Bellenger S, Fevre C, Bellenger J, Tessier C, Narce M & Rialland M (2010) Inhibition of stearoyl-CoA desaturase 1 expression induces CHOP-dependent cell death in human cancer cells. PLoS One 5, e14363.
57. Griffiths B, Lewis CA, Bensaad K, Ros S, Zhang X, Ferber EC, Konisti S, Peck B, Miess H, East P et al. (2013) Sterol regulatory element binding protein-dependent regulation of lipid synthesis supports cell survival and tumour growth. Cancer Metab 1, 3.
58. Williams KJ, Argus JP, Zhu Y, Wilks MQ, Marbois BN, York AG, Kidani Y, Pourzia AL, Akhavan D, Lisiero DN et al. (2013) An essential requirement for the SCAP/SREBP signaling axis to protect cancer cells from lipotoxicity. Cancer Res 73, 2850–2862.
59. Young RM, Ackerman D, Quinn ZL, Mancuso A, Gruber M, Liu L, Giannoukos DN, Bobrovnikova-Marjon E, Diehl JA, Keith B et al. (2013) Dysregulated mTORC1 renders cells critically dependent on desaturated lipids for survival under tumor-like stress. Genes Dev 27, 1115–1131.
60. Lum JJ, DeBerardinis RJ & Thompson CB (2005) Autophagy in metazoans: cell survival in the land of plenty. Nat Rev Mol Cell Biol 6, 439–448.
61. Kamphorst JJ, Cross JR, Fan J, de Stanchina E, Mathew R, White EP, Thompson CB & Rabinowitz JD (2013) Hypoxic and Ras-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids. Proc Natl Acad Sci USA 110, 8882–8887.
62. Lewis CA, Brault C, Peck B, Bensaad K, Griffiths B, Mitter R, Chakravarty P, East P, Dankworth B, Alibhai D et al. (2015) SREBP maintains lipid biosynthesis and viability of cancer cells under lipid- and oxygen-deprived conditions and defines a gene signature associated with poor survival in glioblastoma multiforme. Oncogene 34, 5128–5140.
63. Ackerman D & Simon MC (2014) Hypoxia, lipids, and cancer: surviving the harsh tumor microenvironment. Trends Cell Biol 24, 472–478.
64. Janda CY & Garcia KC (2015) Wnt acylation and its functional implication in Wnt signalling regulation. Biochem Soc Trans 43, 211–216.
65. Rios-Esteves J & Resh MD (2013) Stearoyl CoA desaturase is required to produce active, lipid-modified Wnt proteins. Cell Rep 4, 1072–1081.
66. Kim H, Rodriguez-Navas C, Kollipara RK, Kapur P, Pedrosa I, Brugarolas J, Kittler R & Ye J (2015) Unsaturated fatty acids stimulate tumor growth through stabilization of beta-catenin. Cell Rep 13, 495–503.
67. Varga T, Czimmerer Z & Nagy L (2011) PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation. Biochim Biophys Acta 1812, 1007–1022.
68. Rysman E, Brusselmans K, Scheys K, Timmermans L, Derua R, Munck S, Van Veldhoven PP, Waltregny D, Daniels VW, Machiels J et al. (2010) De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation. Cancer Res 70, 8117–8126.
69. Hilvo M, Gade S, Hyotylainen T, Nekljudova V, Seppanen-Laakso T, Sysi-Aho M, Untch M, Huober J, von Minckwitz G, Denkert C et al. (2014) Monounsaturated fatty acids in serum triacylglycerols are associated with response to neoadjuvant chemotherapy in breast cancer patients. Int J Cancer 134, 1725–1733.
70. Commisso C, Davidson SM, Soydaner-Azeloglu RG, Parker SJ, Kamphorst JJ, Hackett S, Grabocka E, Nofal M, Drebin JA, Thompson CB et al. (2013) Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature 497, 633–637.
71. Salloum D, Mukhopadhyay S, Tung K, Polonetskaya A & Foster DA (2014) Mutant ras elevates dependence on serum lipids and creates a synthetic lethality for rapamycin. Mol Cancer Ther 13, 733–741.
72. Daemen A, Peterson D, Sahu N, McCord R, Du X, Liu B, Kowanetz K, Hong R, Moffat J, Gao M et al. (2015) Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors. Proc Natl Acad Sci USA 112, E4410–E4417.
73. Eberlin LS, Gabay M, Fan AC, Gouw AM, Tibshirani RJ, Felsher DW & Zare RN (2014) Alteration of the lipid profile in lymphomas induced by MYC overexpression. Proc Natl Acad Sci USA 111, 10450–10455.
74. Yoshii Y, Furukawa T, Yoshii H, Mori T, Kiyono Y, Waki A, Kobayashi M, Tsujikawa T, Kudo T, Okazawa H et al. (2009) Cytosolic acetyl-CoA synthetase affected tumor cell survival under hypoxia: the possible function in tumor acetyl-CoA/acetate metabolism. Cancer Sci 100, 821–827.
75. Kamphorst JJ, Chung MK, Fan J & Rabinowitz JD (2014) Quantitative analysis of acetyl-CoA production in hypoxic cancer cells reveals substantial contribution from acetate. Cancer Metab 2, 23.
76. Schug ZT, Peck B, Jones DT, Zhang Q, Grosskurth S, Alam IS, Goodwin LM, Smethurst E, Mason S, Blyth K et al. (2015) Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stress. Cancer Cell 27, 57–71.
77. Comerford SA, Huang Z, Du X, Wang Y, Cai L, Witkiewicz AK, Walters H, Tantawy MN, Fu A, Manning HC et al. (2014) Acetate dependence of tumors. Cell 159, 1591–1602.
78. Mashimo T, Pichumani K, Vemireddy V, Hatanpaa KJ, Singh DK, Sirasanagandla S, Nannepaga S, Piccirillo SG, Kovacs Z, Foong C et al. (2014) Acetate is a bioenergetic substrate for human glioblastoma and brain metastases. Cell 159, 1603–1614.
79. Flavin R, Peluso S, Nguyen PL & Loda M (2010) Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol 6, 551–562.
80. Loftus TM, Jaworsky DE, Frehywot GL, Townsend CA, Ronnett GV, Lane MD & Kuhajda FP (2000) Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors. Science 288, 2379–2381.
81. Wang H, Klein MG, Zou H, Lane W, Snell G, Levin I, Li K & Sang BC (2015) Crystal structure of human stearoyl-coenzyme A desaturase in complex with substrate. Nat Struct Mol Biol 22, 581–585.